Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domains

US9688760B2 · kind B2 · utility

Assignee

• AMGEN RESEARCH (MUNICH) GMBH · DE

Inventors

• Peter Kufer · Munich, DE
• Dirk Nagorsen · Munich, DE
• Juergen Scheele · Munich, DE
• Gerhard Zugmaier · Munich, DE
• Matthias Klinger · Gilching, DE
• Patrick Hoffmann · Munich, DE
• Virginie Naegele · Munich, DE
• Elaine-Pashupati Dopfer · Munich, DE

Key dates

• Filing date: Feb 8, 2014
• Grant date: Jun 27, 2017
• Expiry date: Sep 5, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/70
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates in essence to use of a compound, which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by a therapy which comprises re-directing of T-cells against target cells in a patient. Such a therapy includes, but is not limited to, treatment with an antibody comprising a CD3 binding domain, such as a CD20×CD3 or a CD19×CD3 bispecific single chain antibody, e.g., blinatumomab (MT-103). Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells are also contemplated, as are methods of identifying a compound for administration in the methods of prophylaxis, amelioration and/or treatment. Such anti-adhesive type compounds include, but are not limited to, antibodies, like natalizumab, efalizumab, and etrolizumab; minocycline, (acetyl-)salicyclic acid, astilbin, and flavonoids; and thrombin and pentosanpolysulfate (PPS), or a pharmaceutically acceptable salt thereof.